Castle Biosciences Reports $24.2M Net Loss for 2025 Amidst Medicare Coverage Loss for Key Test

summarizeSummary

Castle Biosciences filed its 2025 annual report, revealing a significant net loss of $24.2 million and a decline in gross margin, primarily due to the discontinuation of Medicare coverage for its DecisionDx-SCC test and the exit from the IDgenetix market. The company is pursuing new growth initiatives and is cooperating with an ongoing HHS OIG subpoena.

check_boxKey Events

• Significant Net Loss in 2025

  The company reported a net loss of $24.2 million for the year ended December 31, 2025, a significant decline from a net income of $18.2 million in 2024. Gross margin decreased to 69.2% from 78.5% in the prior year.

• Medicare Coverage Loss for DecisionDx-SCC

  Medicare coverage for the DecisionDx-SCC test was discontinued by Novitas effective April 24, 2025, and Palmetto/Noridian also recommended no coverage effective August 18, 2024. The company has submitted reconsideration requests for both LCDs.

• Discontinuation of IDgenetix Test

  The IDgenetix test offering was discontinued in May 2025, resulting in an accelerated amortization expense of approximately $20.1 million in the first quarter of 2025.

• New Product Launch and Strategic Acquisitions

  Castle Biosciences commenced a limited launch of its AdvanceAD-Tx test in November 2025, targeting a $33 billion U.S. market. The company also acquired Previse in May 2025 to expand its GI diagnostic offerings and entered a collaboration with SciBase in June 2025 for atopic dermatitis diagnostic tests.

auto_awesomeAnalysis

The 2025 annual report highlights a challenging financial year for Castle Biosciences, marked by a substantial shift from net income to a net loss of $24.2 million and a notable decrease in gross margin. A primary driver of this downturn is the loss of Medicare coverage for the DecisionDx-SCC test, effective April 24, 2025, which significantly impacted dermatologic revenue. Additionally, the company discontinued its IDgenetix test in May 2025, leading to accelerated amortization expenses. While the company is actively expanding its portfolio with the limited launch of AdvanceAD-Tx and strategic acquisitions like Previse and a collaboration with SciBase, these initiatives are in early stages and have not yet offset the financial headwinds. The ongoing subpoena from the U.S. Department of Health and Human Services Office of Inspector General regarding billing practices adds a layer of regulatory uncertainty and potential legal costs. Investors should monitor the company's ability to regain reimbursement for DecisionDx-SCC, the commercial traction of new products, and the resolution of the OIG investigation, as these factors will be critical for future profitability and stock performance. The adoption of Rule 10b5-1 trading plans by key executives for substantial share sales, while pre-planned, could also be perceived negatively by the market.